secwatch / observer
8-K filed September 12, 2022, 7:59 PM ET ticker TXMD CIK 0000025743
leadership confidence high sentiment neutral materiality 0.70

TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing

TherapeuticsMD, Inc.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tommy Thompson

Executive Chairman
TXMD · TherapeuticsMD, Inc.
Effective
2022-09-06
Filed
September 12, 2022, 7:59 PM ET
the Board appointed The Honorable Tommy Thompson, who previously served as the Company’s Chairman of the Board, as the Executive Chairman of the Board.
Appointed (interim)

Mark Glickman

Interim Co-Chief Executive Officer
TXMD · TherapeuticsMD, Inc.
Effective
2022-09-06
Filed
September 12, 2022, 7:59 PM ET
On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers
Departed

Hugh O'Dowd

Chief Executive Officer
TXMD · TherapeuticsMD, Inc.
Effective
2022-09-06
Successor
Brian Bernick, Mark Glickman
Filed
September 12, 2022, 7:59 PM ET
Mr. O’Dowd’s separation as the Company’s Chief Executive Officer is a termination without “Good Cause,”
Appointed (interim)

Brian Bernick

Interim Co-Chief Executive Officer
TXMD · TherapeuticsMD, Inc.
Effective
2022-09-06
Filed
September 12, 2022, 7:59 PM ET
On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tommy Thompson was appointed as Executive Chairman at TherapeuticsMD, Inc..

Action
appointed
Role
Executive Chairman
Exact text from the filing
the Board appointed The Honorable Tommy Thompson, who previously served as the Company’s Chairman of the Board, as the Executive Chairman of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Glickman was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

Action
appointed
Role
Interim Co-Chief Executive Officer
Exact text from the filing
On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh O'Dowd departed as Chief Executive Officer at TherapeuticsMD, Inc..

Action
termination without 'Good Cause'
Role
Chief Executive Officer
Exact text from the filing
Mr. O’Dowd’s separation as the Company’s Chief Executive Officer is a termination without “Good Cause,”
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Bernick was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..

Action
appointed
Role
Interim Co-Chief Executive Officer
Exact text from the filing
On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers
View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-242398
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.